PMID- 22844377
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 4
IP  - 2
DP  - 2012 Aug
TI  - Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant 
      tumors.
PG  - 319-323
AB  - Malignant tumors are the leading cause of mortality worldwide. The search for new 
      biomarkers for the early diagnosis of the onset of cancer to reduce high 
      mortality is crucial. The potential of minimal invasive testing using serum from 
      patients renders auto-antibodies promising biomarkers for cancer diagnosis. In 
      this study, a 181 amino acid peptide of extracellular astrocyte elevated gene-1 
      (AEG-1) was expressed and purified, and the peptide was used in an ELISA assay to 
      detect anti-AEG-1 auto-antibodies (AEG-1-Abs) in 483 serum samples from different 
      cancer patients and 230 serum samples from normal blood donors. The results 
      showed that AEG-1-Abs at titers >/=1:50 were detected in 238 of 483 (49%) cancer 
      patients, and the positive antibody responses in different cancer patients were 
      as follows: 44 of 98 (45%) in breast cancer patients, 48 of 96 (50%) in hepatic 
      carcinoma patients, 43 of 88 (49%) in rectal cancer patients, 51 of 113 (45%) in 
      lung cancer patients, and 52 of 88 (59%) in gastric cancer patients. These 
      results were compared with 0 of 230 (0%) in normal individuals. Moreover, 
      AEG-1-Abs at titers >/=1:50 were also detected in 24 of 94 (26%) cancer patients in 
      TNM stages I and II, and the positive rates of AEG-1-Abs decreased with age. 
      These results suggest that the AEG-1-Ab response acts as a diagnostic biomarker 
      for cancer patients with AEG-1-positive expression, and may also prove to be a 
      possible inducer, with substantial immunity against AEG-1 by immunization 
      boosting with AEG-1 vaccines.
FAU - Chen, Xi
AU  - Chen X
AD  - Department of Medicine Laboratory and Research Center, Tangdu Hospital, Fourth 
      Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
FAU - Dong, Ke
AU  - Dong K
FAU - Long, Min
AU  - Long M
FAU - Lin, Fang
AU  - Lin F
FAU - Wang, Xi
AU  - Wang X
FAU - Wei, Junxia
AU  - Wei J
FAU - Ren, Jihong
AU  - Ren J
FAU - Zhang, Huizhong
AU  - Zhang H
LA  - eng
PT  - Journal Article
DEP - 20120525
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC3402762
EDAT- 2012/07/31 06:00
MHDA- 2012/07/31 06:01
PMCR- 2013/08/01
CRDT- 2012/07/31 06:00
PHST- 2012/01/17 00:00 [received]
PHST- 2012/04/23 00:00 [accepted]
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2012/07/31 06:01 [medline]
PHST- 2013/08/01 00:00 [pmc-release]
AID - ol-04-02-0319 [pii]
AID - 10.3892/ol.2012.734 [doi]
PST - ppublish
SO  - Oncol Lett. 2012 Aug;4(2):319-323. doi: 10.3892/ol.2012.734. Epub 2012 May 25.